β
Outcome MeasureOther

CGI-I

Clinical Global Impression – Improvement Scale

1 Paper in Blossom

Clinical Thresholds

17
Very much improved
Score 1–1
Much improved
Score 2–2
Minimally improved
Score 3–3
No change
Score 4–4
Minimally worse
Score 5–5
Much worse
Score 6–6
Very much worse
Score 7–7

Outcome Data Across Studies

Reported results for CGI-I across 1 study with quantitative data.

Outcome data across 1 study arm–timepoint observations
SD
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)2119———

Papers Using CGI-I

Open Accessindividual

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

This open-label Phase II trial (n=19) investigates the safety, tolerability, and efficacy of synthetic psilocybin (COMP360) as an adjunct to selective serotonin reuptake inhibitors (SSRIs) in adults with treatment-resistant depression (TRD). The study found no serious treatment-emergent adverse events or increased suicidal ideation. It reported a significant decrease in depression (MADRS) and Clinical Global Impression-Severity (CGI-S) scores at week 3, with response and remission observed in 42.1% of participants.

Published
Journal
Neuropharmacology
Authors
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O'keane, V., Peck, S. K., Simmons, H., Sisa, C., Stansfield, S. C., Tsai, J., Williams, S., Malievskaia, E.

Quick Facts

Full Name
Clinical Global Impression – Improvement Scale
Domain
Other
Papers Indexed
1
Score Range
1–7
Interpretation
Lower = better
Unit
points
Reference
Visit
All Measures